Finanzas de Amgen Inc (AMGN)AMGNAmgen Inc

Amgen Inc (AMGN) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Other products, accounting for 16.9% of total sales, equivalent to $1.70B. Other significant revenue streams include Repatha and Prolia. Understanding this composition is critical for investors evaluating how AMGN navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Amgen Inc maintains a gross margin of 72.64%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 35.55%, while the net margin is 23.62%. These profitability ratios, combined with a Return on Equity (ROE) of 91.47%, provide a clear picture of how effectively AMGN converts its operational activities into shareholder value.

In the context of the broader market, AMGN competes directly with industry leaders such as GILD and GMAB. With a market capitalization of $230.37B, it holds a leading position in the sector. When comparing efficiency, AMGN's gross margin of 72.64% stands against GILD's 79.76% and GMAB's 92.73%. Such benchmarking helps identify whether Amgen Inc is trading at a premium or discount relative to its financial performance.

Amgen's financial performance is strong, with a 9.9% year-over-year revenue growth in FY 2025, reaching nearly $36.7 billion, and a net income of approximately $7.7 billion, resulting in a net margin of about 21%. The gross margin has also been impressive, averaging around 72% in recent quarters.